These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28618451)

  • 21. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
    De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
    Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
    Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
    PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores J; Bárcena P; Rasillo A; Sayagues JM; Sánchez ML; Hernandez-Campo P; Hernandez Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Orfao A
    Leukemia; 2008 Jun; 22(6):1175-83. PubMed ID: 18337765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.
    Porwit A; Béné MC; Duetz C; Matarraz S; Oelschlaegel U; Westers TM; Wagner-Ballon O; Kordasti S; Valent P; Preijers F; Alhan C; Bellos F; Bettelheim P; Burbury K; Chapuis N; Cremers E; Della Porta MG; Dunlop A; Eidenschink-Brodersen L; Font P; Fontenay M; Hobo W; Ireland R; Johansson U; Loken MR; Ogata K; Orfao A; Psarra K; Saft L; Subira D; Te Marvelde J; Wells DA; van der Velden VHJ; Kern W; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2023 Jan; 104(1):27-50. PubMed ID: 36537621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
    Sun JF; Yang B; Zhang L; Huang Y; Yang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Changes of CD34(+) and CD71(+)CD45(-) cell levels in bone marrow of MDS and AA patients].
    Yan ZY; Tian X; Li Y; Yang MR; Zhang S; Wang XM; Zhang HX; Cheng NY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):382-6. PubMed ID: 24763009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of CD34(-) and CD34(+) cell apoptosis and proliferation in bone marrow of patients with MDS and their impact on survival.
    Xia B; Guo Q; Zhao DD; Zhao HF; Han XP; Wang H; Wu XX; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1392-7. PubMed ID: 23257440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].
    Liu BN; Fu R; Wang HQ; Li LJ; Yue LZ; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Xing LM; Guan J; Wang J; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):480-3. PubMed ID: 22967386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome.
    Malcovati L; Della Porta MG; Lunghi M; Pascutto C; Vanelli L; Travaglino E; Maffioli M; Bernasconi P; Lazzarino M; Invernizzi R; Cazzola M
    Leukemia; 2005 May; 19(5):776-83. PubMed ID: 15789068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.
    Kornblau SM; Cohen AC; Soper D; Huang YW; Cesano A
    Cytometry B Clin Cytom; 2014 Nov; 86(6):383-96. PubMed ID: 24106013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological implications of circulating CD34(+) cells in myelodysplastic syndromes.
    Marisavljevic D; Kraguljac-Kurtovic N
    J BUON; 2010; 15(4):753-7. PubMed ID: 21229641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
    Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
    Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes.
    Johansson U; McIver-Brown N; Cullen M; Duetz C; Dunlop A; Oelschlägel U; Psarra K; Subirá D; Westers TM
    Cytometry B Clin Cytom; 2023 Mar; 104(2):115-127. PubMed ID: 34931733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunophenotypic clustering of myelodysplastic syndromes.
    Maynadié M; Picard F; Husson B; Chatelain B; Cornet Y; Le Roux G; Campos L; Dromelet A; Lepelley P; Jouault H; Imbert M; Rosenwadj M; Vergé V; Bissières P; Raphaël M; Béné MC; Feuillard J;
    Blood; 2002 Oct; 100(7):2349-56. PubMed ID: 12239142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.
    Ogata K; Nakamura K; Yokose N; Tamura H; Tachibana M; Taniguchi O; Iwakiri R; Hayashi T; Sakamaki H; Murai Y; Tohyama K; Tomoyasu S; Nonaka Y; Mori M; Dan K; Yoshida Y
    Blood; 2002 Dec; 100(12):3887-96. PubMed ID: 12393641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.